Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice

Hepatology

Volumn 37, Issue 4, 2003, Pages 880-886

  Barone, Michele ^a   Maiorano, Eugenio ^a   Ladisa, Roberta ^a   Cuomo, Rosario ^b   Pece, Antonia ^a   Berloco, Pasquale ^c   Caruso, Maria Lucia ^c   Valentini, Anna Maria ^c   Iolascon, Achille ^d   Francavilla, Antonio ^a   Di Leo, Alfredo ^c   Ierardi, Enzo ^d  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; URSODEOXYCHOLIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLYSIS; DIET; DIETARY INTAKE; HEPATITIS B VIRUS; HISTOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL; LIVER HISTOLOGY; LIVER TUMOR; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 0037382869     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50175     Document Type: Article

References (33)

1. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985;230:1157-1160.
2. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A 1987;84:6909-6913.
3. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990;50:3400-3407.
4. Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. HEPATOLOGY 1994;20:1162-1172.
5. Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. HEPATOLOGY 1995;21:620-626.
6. Pasquinelli C, Bhavani K, Chisari FV. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992;52:2823-2829.
7. Barone M, Panella C, Angelini A, Romanelli D, Francavilla A. Studies in vitro on the influence of ursodeoxycholate sodium salt (UDC) on hepatocyte proliferation. J Surg Oncol 1993;3:8-13.
8. Barone M, Francavilla A, Polimeno L, Ierardi E, Romanelli D, Berloco P, Di Leo A, et al. Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies. HEPATOLOGY 1996;23:1159-1166.
9. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, et al. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology 1999;116:179-186.
10. Barone M, Berloco P, Ladisa R, Ierardi E, Caruso ML, Valentini AM, Notarnicola M, et al. Demonstration of a direct stimulatory effect of bile salts on rat colonic epithelial cell proliferation. Scand J 2002; 7:88-94.
11. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. HEPATOLOGY 2001;34: 523-528.
12. Lam KH, Wei WI, Ho HC, Ho CM. Whole organ sectioning of mixed parotid tumors. Am J Surg 1990;160:377-381.
13. Bauman JW, Goldsworthy TL, Dunn CS, Fox TR. Inhibitory effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on rat hepatocyte proliferation induced by 2/3 partial hepatectomy. Cell Prolif 1995;28:437-451.
14. van Noorden S. Tissue preparation and immunostaining techniques for light microscopy. In: Polak JM, Van Noorden S, eds. Immunocytochemistry: Modern Methods and Applications. 2nd ed. Bristol: Wright PSG, 1986:47-48.
15. Kamada S, Maeda M, Tsuji A. Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene asa pre-labeling reagent. J Chromatogr 1983;272:29-41.
16. Street JM, Trafford DJH, Makin HLJ. Extraction and fractionation of bile acids and their conjugated using pre-packed microparticulate silica cartridges (Sep-Pak SIL and Bond Elut C18). J Chromatogr 1985;343:259-270.
17. Koike K, Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Tsutsumi T, Kimura S. Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis. Cancer Lett 1998;134:181-186.
18. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A 1995;92:11215-11219.
19. Ahn JY, Chung EY, Kwun HJ, Jang KL. Transcriptional repression of p21(waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. Gene 2001;275:163-168.
20. Bouchard M, Giannakopoulos S, Wang EH, Tanese N, Schneider RJ. Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 2001; 75:4247-4257.
21. Vujanovic NL, Polimeno L, Azzarone A, Francavilla A, Chambers WH, Starzl TE, Herberman RB, et al. Changes of liver-resident NK cells during liver regeneration in rats. J Immunol 1995;154:6324-6338.
22. Rusticali AG, Sommacal S, Frigerio G. Gallstones dissolving agents: ursodeoxycholic acid. In: Braga PC, Guslandi M, Tittobello A, eds. Drugs in Gastroenterology. New York: Raven, 1991:349-368.
23. Panella C, Ierardi E, De Marco MF, Barone M, Guglielmi FW, Polimeno L, Francavilla A. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease? Ital J Gastroenterol 1995;27:256-258.
24. Francavilla A, Polimeno L, Barone M, Azzarone A, Starzl TE. Hepatic regeneration and growth factors. J Surg Oncol 1993;3:1-7.
25. Capuano F, Barone M, D'Eri N, Russo E, Varone D, Francavilla A, Papa S. Ursodeoxycholate promotes protein phosphorylation in the cytosol of rat hepatocytes. Biochem Mol Biol Int 1997;41:329-337.
26. Druker BJ, Mamon HJ, Roberts TM. Oncogenes, growth factors, and signal transduction. N Engl J Med 1989;321:1383-1391.
27. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122:985-993.
28. Rao YP, Studer EJ, Stravitz RT, Gupta S, Qiao L, Dent P, Hylemon PB. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. HEPATOLOGY 2002;35:307-314.
29. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
30. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
31. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-2799.
32. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 1999;6:842-854.
33. Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe N, Boyer JL. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. HEPATOLOGY 2002;36:49-54.